読み込み中
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
前日終値
$2.90
+$0.06 · +2.11%
日中の時刻はETです。市場データは遅延する場合があります。
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
日中レンジ
現在 $2.90
52週レンジ
現在 $2.90
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
60
適正価値
センチメント
42
まちまち
リスク
67
高リスク
モメンタム
69
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
日中レンジ
現在 $2.90
52週レンジ
現在 $2.90
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4052万 USD | 3231.4万 USD | 7812.3万 USD | 1971.2万 USD | 2554.4万 USD |
| 売上原価 | — | 1.99億 USD | 606.4万 USD | 633.7万 USD | 505.3万 USD |
| 粗利益 | 4052万 USD | −1.67億 USD | 7205.9万 USD | 1337.5万 USD | 2049.1万 USD |
| 研究開発 | 8995.3万 USD | 1.99億 USD | 1.78億 USD | 1.75億 USD | 1.43億 USD |
| 販売・一般管理 | 4990.3万 USD | 7198.7万 USD | 6965.3万 USD | 7070.4万 USD | 7618.3万 USD |
| 営業費用 | 1.4億 USD | 8421.9万 USD | 2.41億 USD | 2.39億 USD | 2.14億 USD |
| 受取利息 | 831万 USD | 1406.2万 USD | 1756.6万 USD | 551.8万 USD | 60.7万 USD |
| 支払利息 | 617.1万 USD | — | — | — | — |
| 減価償却費と償却費 | 527.7万 USD | 580.9万 USD | 606.4万 USD | 633.7万 USD | 505.3万 USD |
| 営業利益 | −9933.6万 USD | −2.51億 USD | −1.69億 USD | −2.26億 USD | −1.93億 USD |
| 純利益 | −1.6億 USD | −2.37億 USD | −1.53億 USD | −2.2億 USD | −1.93億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.00
上昇余地（72.41%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1496.38万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1217.39万0.12%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1149.28万0.01%787.4億 USD0.19%$278.94+0.49%
iShares Russell 2000 Growth ETFIWO366.55万0.03%139.17億 USD0.24%$356.78+0.94%
Vanguard Extended Market ETFVXF350.52万0.00%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB304.82万0.03%108.2億 USD0.44%$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA198.62万0.01%218.24億 USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO176.26万0.01%180億 USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
